Abpro Corporation (ABP) Stock Analysis
DELISTED 2026
What happened to Abpro Corporation (ABP) stock?
Abpro Corporation (ABP) no longer trades on public markets. It was delisted in March 2026. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Abpro Corporation (ABP) trades at $0.522. Abpro Holdings, Inc. is a biotechnology company focused on developing antibody therapeutics for immuno-oncology, ophthalmology, and autoimmunity. Their DiversImmune platform aims to address bottlenecks in antibody therapeutics development. Market cap: $1.06M, Sector: Healthcare.
Last analyzed: Jun 1, 2026Analyst Coverage for ABP: ABP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ABP against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
ABP: the 2 scored disciplines are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →Abpro Corporation (ABP) Healthcare & Pipeline Overview
Abpro Holdings, Inc. is a biotechnology company specializing in antibody therapeutics for immuno-oncology, ophthalmology, and autoimmunity, utilizing its DiversImmune platform. With lead candidates like ABP-100 and ABP-201, the company targets significant unmet needs in cancer and vascular eye diseases, operating in a competitive biotech landscape.
What Is the Investment Thesis for ABP?
Abpro Holdings, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's DiversImmune platform offers a novel approach to antibody discovery, potentially leading to breakthrough therapeutics in immuno-oncology and ophthalmology. Key value drivers include the successful clinical development and commercialization of ABP-100 and ABP-201. Upcoming clinical trial results for ABP-100 in breast, gastric, and colorectal cancers, expected in 2027, could serve as a significant catalyst. A strategic partnership with Abpro Bio Co. Ltd and NJCTTQ could accelerate development. However, the company's negative profit margin of -7670.5% and gross margin of -55.2% highlight significant financial challenges. The company's small size (6 employees) and limited resources pose risks to its ability to execute its development programs. Investors should carefully consider the inherent risks and uncertainties associated with biotechnology investments, particularly for companies in early stages of development.
Based on FMP financials and quantitative analysis
ABP Key Highlights
Abpro Holdings, Inc. focuses on developing antibody therapeutics for immuno-oncology, ophthalmology, and autoimmunity.
- The company's DiversImmune platform aims to address bottlenecks in the antibody therapeutics industry.
- Lead product candidate ABP-100 is being developed for the treatment of breast, gastric, and colorectal cancers.
- ABP-201 is being developed for the treatment of vascular diseases of the eye.
- The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ.
Who Are ABP's Competitors?
ABP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.21% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ABP's Key Strengths?
Proprietary DiversImmune platform
- Focus on antibody therapeutics
- Strategic partnerships
- Pipeline of clinical candidates
What Are ABP's Weaknesses?
Limited financial resources
- Small number of employees
- Early stage of development
- Negative profit and gross margins
What Could Drive ABP Stock Higher?
Clinical trial results for ABP-100 in breast, gastric, and colorectal cancers expected in 2027.
- Strategic partnership with Abpro Bio Co. Ltd and NJCTTQ to accelerate development.
- Advancement of ABP-201 for the treatment of vascular diseases of the eye.
What Are the Key Risks for ABP?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for ABP-100 and ABP-201.
- Competition from larger pharmaceutical companies with greater resources.
- Regulatory hurdles and delays in obtaining approvals.
- Limited financial resources and negative profit margins.
- Dependence on strategic partnerships for funding and expertise.
What Are the Growth Opportunities for ABP?
- Expansion of ABP-100 Clinical Trials: Abpro has the opportunity to expand the clinical trials for ABP-100 to include additional cancer types and combination therapies. The global cancer therapeutics market is projected to reach $286 billion by 2028. Successful clinical trials and subsequent regulatory approvals could drive significant revenue growth for Abpro, with potential partnerships with larger pharmaceutical companies to accelerate commercialization. This expansion would require additional funding and resources, but the potential return on investment is substantial, especially if ABP-100 demonstrates superior efficacy and safety compared to existing treatments. Timeline: Ongoing, with potential for accelerated expansion in 2027 pending clinical trial results.
- Advancement of ABP-201 for Ocular Diseases: Abpro can capitalize on the growing market for treatments for vascular diseases of the eye by advancing the clinical development of ABP-201. The global ophthalmology market is projected to reach $53.7 billion by 2029. Successful clinical trials and regulatory approval could position ABP-201 as a valuable treatment option for conditions such as age-related macular degeneration (AMD) and diabetic retinopathy. This growth opportunity requires significant investment in clinical trials and regulatory affairs, but the potential market size and unmet need make it a compelling area of focus. Timeline: Ongoing, with potential for regulatory submission in 2028.
- Strategic Partnerships and Collaborations: Abpro can leverage strategic partnerships and collaborations to accelerate the development and commercialization of its antibody therapeutics. Collaborating with larger pharmaceutical companies or research institutions can provide access to funding, expertise, and resources that Abpro may lack. These partnerships can also help to validate Abpro's technology and increase its visibility within the industry. The success of this growth opportunity depends on Abpro's ability to identify and secure mutually beneficial partnerships. Timeline: Ongoing.
- Expansion of DiversImmune Platform Applications: Abpro can expand the applications of its DiversImmune platform to develop antibody therapeutics for a wider range of diseases. The platform's versatility and efficiency make it well-suited for generating antibodies against various targets. By expanding its pipeline of preclinical and clinical candidates, Abpro can diversify its revenue streams and reduce its reliance on ABP-100 and ABP-201. This growth opportunity requires investment in research and development, but the potential for long-term growth is significant. Timeline: Ongoing.
- Geographic Expansion: Abpro has the opportunity to expand its geographic presence by establishing operations or partnerships in key markets such as Europe and Asia. The global biotechnology market is growing rapidly in these regions, driven by increasing healthcare spending and a growing demand for innovative therapies. By expanding its geographic footprint, Abpro can access new markets and increase its revenue potential. This growth opportunity requires careful planning and execution, but the potential benefits are substantial. Timeline: Potential expansion starting in 2028.
What Are ABP's Competitive Advantages?
- DiversImmune platform (proprietary technology)
- Strategic partnerships (Abpro Bio Co. Ltd and NJCTTQ)
- Pipeline of antibody therapeutics (ABP-100 and ABP-201)
- Focus on unmet medical needs
What Does ABP Do?
Abpro Holdings, Inc., formerly known as Abpro Corporation, was founded in 2004 and is headquartered in Woburn, Massachusetts. The company focuses on developing next-generation antibody therapeutics to address unmet needs in immuno-oncology, ophthalmology, and autoimmunity. Abpro's core technology is its DiversImmune platform, which aims to overcome the limitations of traditional antibody discovery and development processes. This platform is designed to generate a diverse library of antibodies with enhanced therapeutic potential. Abpro's lead product candidate, ABP-100, is being developed for the treatment of various cancers, including breast, gastric, and colorectal cancers. ABP-100 targets a specific tumor-associated antigen and is designed to elicit a potent anti-tumor response. The company is also developing ABP-201 for the treatment of vascular diseases of the eye, such as age-related macular degeneration (AMD) and diabetic retinopathy. ABP-201 is designed to inhibit angiogenesis, the formation of new blood vessels that contribute to these diseases. Abpro has established strategic partnerships with Abpro Bio Co. Ltd and NJCTTQ to advance its research and development efforts. The company changed its name to Abpro Holdings, Inc. in November 2024, reflecting its evolution and strategic direction in the biotechnology sector. Despite its innovative platform, Abpro operates in a highly competitive environment, facing challenges related to clinical development, regulatory approvals, and commercialization.
What Products and Services Does ABP Offer?
- Develops antibody therapeutics for immuno-oncology.
- Creates antibody therapeutics for ophthalmology.
- Develops antibody therapeutics for autoimmunity.
- Utilizes the DiversImmune platform for antibody discovery.
- Focuses on unmet needs in cancer and vascular eye diseases.
- Conducts preclinical and clinical research.
How Does ABP Make Money?
- Develops and out-licenses antibody therapeutics.
- Generates revenue through strategic partnerships.
- Seeks to commercialize proprietary drug candidates.
- Focuses on research and development of novel antibodies.
What Industry Does ABP Operate In?
Abpro Holdings, Inc. operates within the highly competitive biotechnology industry, characterized by rapid innovation, stringent regulatory requirements, and significant capital investment. The global biotechnology market is projected to reach $3.44 trillion by 2033, growing at a CAGR of 12.3% from 2024. Abpro's focus on antibody therapeutics places it in direct competition with established pharmaceutical companies and other emerging biotech firms. Key trends in the industry include the increasing adoption of personalized medicine, the development of novel drug delivery systems, and the growing importance of immunotherapy. Abpro's DiversImmune platform aims to differentiate it from competitors by offering a more efficient and versatile approach to antibody discovery.
Who Are ABP's Key Customers?
- Pharmaceutical companies (potential partners/licensees)
- Patients with cancer (ABP-100 target)
- Patients with vascular eye diseases (ABP-201 target)
Key Financial Metrics
Return on equity for Abpro Corporation stands at 83.2%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.07 means current liabilities exceed short-term assets, a liquidity point worth watching.
Abpro Corporation (ABP) Valuation Context
Valued at $1.06M, ABP is classified as a micro-cap stock.
Company Profile
Abpro Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Woburn, US. The company is led by CEO Jin Wook Suk. ABP has traded publicly since 2022.
Financial Health
Abpro Corporation's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Forward Outlook
Wall Street analysts project Abpro Corporation revenue of about $238K for fiscal 2026, with EPS near $-6.90.
ABP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Abpro has recently seen increased insider buying, suggesting confidence from management in the company's future prospects.
- Social sentiment has shifted positively, with discussions highlighting the potential of their innovative antibody therapies.
- Recent partnerships and collaborations have been well-received, indicating growing trust from the market in their research capabilities.
- Community sentiment reflects optimism about upcoming clinical trial results, which could validate their technology and drive further interest.
Bear Case
- Despite positive sentiment, there are concerns about the competitive landscape in the biotech sector, with many players vying for market share.
- Recent discussions indicate skepticism regarding the timeline for product commercialization, which could delay revenue generation.
- Some community members express caution over the company's cash burn rate, raising questions about financial sustainability in the near term.
- Market perception remains cautious due to overall volatility in the biotech industry, which can impact investor confidence.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2024 | $183,000 | -$6M | -$17.70 |
Based on FMP financials and quantitative analysis
ABP Latest News
No recent news available for ABP.
Leadership: Jin Wook Suk
Unknown
Information about Jin Wook Suk's background is not available in the provided data. Therefore, it is not possible to provide details about their career history, education, or previous roles.
Track Record: Information about Jin Wook Suk's track record is not available in the provided data. Therefore, it is not possible to provide details about key achievements, strategic decisions, or company milestones under their leadership.
What Investors Ask About Abpro Corporation (ABP) — Healthcare
What happened to Abpro Corporation (ABP) stock?
Abpro Corporation (ABP) no longer trades on public markets. It was delisted in March 2026. The figures below are historical and are not a current quote.
Can I still buy ABP shares?
No. ABP stopped trading on public markets in March 2026, so the shares are not available through a broker. Anything you see quoted for ABP elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before ABP stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Abpro Corporation. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Abpro Corporation do?
Abpro Holdings, Inc. is a biotechnology company dedicated to the discovery and development of antibody therapeutics. Utilizing its proprietary DiversImmune platform, Abpro aims to create novel treatments for diseases in immuno-oncology, ophthalmology, and autoimmunity. The company's lead product candidates, ABP-100 and ABP-201, target cancers and vascular eye diseases, respectively.
What do analysts say about ABP stock?
Due to the limited information available, a comprehensive analyst consensus on Abpro Holdings, Inc. (ABP) is not accessible. However, key valuation metrics to consider include the company's market capitalization, profit margin, and gross margin. Given the negative profit margin of -7670.5% and gross margin of -55.2%, Abpro faces significant financial challenges.
What are the main risks for ABP?
Abpro Holdings, Inc. faces several significant risks inherent to the biotechnology industry. Clinical trial failures for ABP-100 and ABP-201 pose a major threat, as these are the company's lead product candidates. Competition from larger pharmaceutical companies with greater resources could hinder Abpro's ability to gain market share.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO background and track record.
- Analyst consensus data is unavailable.
- Competitor information is limited.